Entero Therapeutics (NASDAQ:ENTO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Entero Therapeutics (NASDAQ:ENTO) to a hold rating in a research note issued to investors on Friday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Entero Therapeutics in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Entero Therapeutics Stock Performance

Shares of NASDAQ ENTO opened at $4.35 on Friday. The business has a fifty day simple moving average of $2.77 and a 200 day simple moving average of $1.83. Entero Therapeutics has a one year low of $0.97 and a one year high of $5.47.

Entero Therapeutics (NASDAQ:ENTO) last issued its earnings results on Thursday, August 14th. The company reported ($0.42) EPS for the quarter.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.